Cook MyoSite
15
0
4
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 20/100
13.3%
2 terminated/withdrawn out of 15 trials
75.0%
-11.5% vs industry average
33%
5 trials in Phase 3/4
100%
6 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia
Role: collaborator
REVIVE Prospective Registry Cohort Study
Role: collaborator
Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury
Role: lead
Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence
Role: lead
Expanded Access Program for Autologous Muscle Derived Cells (AMDCs)
Role: lead
Autologous Muscle Derived Cells for Treatment of Tongue Dysphagia
Role: collaborator
Observational Registry for Iltamiocel Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence
Role: lead
Japanese Bridging Study of Autologous Muscle Derived Cells Compared to Placebo for Female Urinary Sphincter Repair(JPN1)
Role: lead
Autologous Cell Therapy for Treatment of Fecal Incontinence
Role: lead
An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells as Therapy for Stress Urinary Incontinence
Role: lead
Autologous Muscle Derived Cells for Female Urinary Sphincter Repair
Role: lead
Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery
Role: lead
Autologous Cell Therapy for Ischemic Heart Failure
Role: lead
Autologous Cell Therapy for Female Stress Urinary Incontinence
Role: lead
Autologous Muscle Derived Cells Female Stress Urinary Incontinence Clinical Study
Role: lead
All 15 trials loaded